Novartis fined 100K for breach of code

The complaint, made by Boehringer Ingelheim and Pfizer who promote rival COPD therapy tiotropium (Spiriva), were in relation to a detail aid for sales staff.

Novartis was found to have violated the code with claims of “improved bronchodilation with Onbrez Breezhaler”, “significantly greater improvement in lung function” and “clinically important improvement in breathlessness over 26 weeks”.

A separate complaint from La Trobe University public health lecturer Dr Ken Harvey led to Pfizer being fined $50